

J004 Rec'd PCT/PTO 19 OCT 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: SUGIMURA5

In re Application of:)	Art Unit:
)	
SUGIMURA et al.)	Examiner:
)	
Serial No.: 10/527,823)	Washington, D.C.
)	
Filed: March 14, 2005)	October 19, 2005
)	
For: HUMAN ANTI-HUMAN MCP-1)	
ANTIBODY AND FRAGMENT OF...)	Confirmation No.: 4585
)	

STATEMENTS IN SUPPORT OF SEQUENCE LISTING REQUIREMENTS

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop **Amendment**
401 Dulany Street
Alexandria, VA 22314

Sir:

Attached hereto is a 3½" disk containing the
"Sequence Listing" in computer readable form in accordance
with 37 C.F.R. §1.821(e) as filed in application no.
10/527,823 on March 14, 2005.

I hereby state, in accordance with 37 C.F.R.
§1.821(f), that the content of the attached computer readable
copy of the sequence listing and the paper copy as originally
filed are believed to be the same.

I hereby also state, in accordance with 37 C.F.R.
§1.821(g), that the submission is not believed to include new
matter.

Appln No.: 10/527,823

Response date March 14, 2005

Reply to Notice to Comply August 25, 2005

If the examiner has any questions or comments concerning the sequence listing in the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By:



Allen C. Yun

Registration No. 37,971

ACY:pp

624 Ninth Street, N.W.


Suite 300

Washington, D.C. 20001

Facsimile: (202) 737-3528

Telephone: (202) 628-5197

G:\BN\A\Aoyb\Sugimura5\pto\response to sequence disk.doc


20520



UNITED STATES PATENT AND TRADEMARK OFFICE

295

4078

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/527,823	FIRST NAMED APPLICANT Kazuhisa Sugimura	ATTY. DOCKET NO. SUGIMURA5
---	--	-------------------------------


INTERNATIONAL APPLICATION NO.

PCT/JP03/11560

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

09/10/2003

001444
BROWDY AND NEIMARK, P.L.L.C.
624 NINTH STREET, NW
SUITE 300
WASHINGTON, DC 20001-5303



CONFIRMATION NO. 4585
371 FORMALITIES LETTER
OC000000016782070
OC000000016782070

SEA = 25002005

Date Mailed: 08/25/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of **\$200** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$-800** for a Large Entity:

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000): Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- Total additional claim fee(s) for this application is **\$ 200**
 - **\$200** for 3 independent claims over 3.

(A previous payment of \$1000 will be applied to the additional fees indicated above.)

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

DEBORAH D WILLIAMS

Telephone: (703) 308-9140 EXT 205

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/527,823	PCT/JP03/11560	SUGIMURA5

FORM PCT/DO/EO/922 (371 Formalities Notice)